ClinicalTrials.gg
RecruitingNCT07176650Updated Mar 16, 2026

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

A Phase 1 interventional study of HLX13 and Yervoy in Hepatocellular Carcinoma (HCC), sponsored by Shanghai Henlius Biotech. Recruiting at 51 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,310 studies in Carcinoma, Hepatocellular with a site in China — 486 open to participants now, 558 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
202nd of 1,034
246 · median 78
Started
2025
with 121 others
Phase 1
138 of 1,310
60 open now
Primary completion
2026-12
later than 302 of 557 live
Registered
1,151st of 1,310
by date

Among the 1,310 studies in Carcinoma, Hepatocellular with a site in China, this one is the 202nd largest by planned enrollment of the 1,034 interventional ones that give a count, is one of 122 that started in 2025, is one of 138 in phase 1, reaches primary completion later than 302 of the 557 other live ones, and was the 1,151st registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

486 of the 1,310 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

481 more — sign in →

All 486 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,310 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, parallel-controlled, phase I clinical study to evaluate the PK characteristics, safety, efficacy, and immunogenicity of HLX13 and US-sourced YERVOY® in patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must have signed and dated an IRB/IEC-approved written form (ICF) in accordance with regulatory and institutional guidelines.
  2. Male or female, 18 years ≤ age ≤ 65 years at the time of signing the ICF.
  3. Body weight: 50 kg-85 kg.
  4. diagnosed hepatocellular carcinoma (HCC); and must have an advanced HCC, defined as: a) not eligible for curative surgical and/or locoregional therapies; or b) progressive disease after surgical and/or locoregional therapies. Subjects with only a radiologic diagnosis of hepatocellular carcinoma may be enrolled for screening in the study but histological confirmation is mandatory prior to randomization.
  5. At least one as assessed by investigator based on v1.1 within 4 weeks prior to the first dose in this study. The measurable lesion is not from sites that have been previously treated with surgery, radiotherapy, and/or locoregional therapy.
  6. No systemic therapy for or advanced hepatocellular carcinoma prior to screening. Note: prior or adjuvant systemic therapy is permitted if recurrence occurs ≥12 months after treatment completion.
  7. (ECOG) performance status (PS) 0 within 7 days prior to the first dose.
  8. Cirrhotic status of Class A within 7 days prior to the first dose.
  9. (LVEF) ≥ 50% as measured by echocardiography.
  10. Normal major organ functions prior to the first dose.
  11. For patients with active virus (HBV), the HBV-DNA must be less than 500 IU/mL or 2500 copies/mL within 28 days prior to the randomization, an anti-HBV treatment (e.g., entecavir) has been started prior to the randomization, and patients are willing to continue the treatment during this study. Patients with positive must agree to receive standard anti-viral therapy per the local standard of care.
  12. Women of should have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to the first dose.

Exclusion criteria

Exclusion Criteria:

  1. With other histopathological types of hepatocellular carcinoma, including fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or mixed cholangiocarcinoma and hepatocellular carcinoma.
  2. Other active within 3 years prior to or at screening except for localized tumors that have been cured such as basal cell carcinoma, squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
  3. Liver transplant, or organ allograft or bone marrow transplantation prior to screening, or the above transplantation is scheduled during the study.
  4. History of hepatic encephalopathy prior to screening.
  5. ascites.
  6. Patients with tumor thrombus at the main portal vein (Vp4), or inferior vena cava prior to screening, or clear invasion into the bile duct, or HCC with ≥50% liver occupation.
  7. Presence of nervous system disorders at screening.
  8. Evidence of portal hypertension with bleeding esophageal or gastric varices within 6 months prior to the randomization. The aforementioned patients have undergone endoscopy to exclude those with high hemorrhage risk may be enrolled. For a patient receiving endoscopy within 6 months prior to randomization, repeat examination is not required.
  9. Any other hemorrhage/bleeding event > Grade 3 within 3 months prior to screening except for esophageal or gastric varices.
  10. History of non-healing wounds, bone fractures, or ulcers at risk of bleeding within 3 months prior to randomization.
  11. Major surgical procedure, open , or significant traumatic injury within 28 days prior to the randomization or those who receive minor surgical procedures (e.g., core biopsy) within 7 days prior to randomization.
  12. Known active or suspected diseases prior to screening. Patients with stable disease who do not require systemic therapy may also participate.
  13. Treatment with systemic (> equivalent dose of 10 mg/day prednisone) or other immunosuppressive agents within 14 days prior to the first dose or during the study. However, for patients with conditions other than active autoimmune diseases, inhaled or topical steroids or adrenocortical hormone replacement therapy (no more than the equivalent dose of 10 mg/day prednisone) are allowed.
  14. Active co-infection with both and C (or detectable HBV surface antigen or HBV-DNA and at screening), or hepatitis D infection in subjects with hepatitis B.
  15. Subjects with a history of co-infection with both hepatitis B and C.
  16. (HIV) infection prior to screening (or positive anti-HIV at screening).
  17. Any active infections (including, but not limited to bacteria, fungi, mycoplasma, chlamydia, and herpes zoster virus) requiring systemic treatment within 14 days prior to screening.
  18. Uncontrolled cardiovascular diseases within 6 months prior to screening.
  19. Known interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, and severe lung function abnormalities that may impede the investigators' diagnosis and management of drug-related pulmonary toxicity prior to screening.
  20. Patients who have used traditional Chinese herbs or medicines with anti-tumor indications within 14 days prior to randomization.
  21. Patients who have received treatment with within 28 days prior to randomization. Those who received inactivated viral vaccines for seasonal influenza or COVID-19 are eligible.
  22. Patients who have received any T-cell costimulatory agents or immune checkpoint blockade therapy, including but not limited to cytotoxic T lymphocyte-associated antigen-4 () inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors, or other agents that target T cells.
  23. Radical radiotherapy within 4 weeks prior to randomization.
  24. Other prior/concomitant therapy: a) Treatment with strong inducers within 1 week prior to randomization, including rifampin (and its analogues) or St. John's wort. b) Use of anticoagulants such as, warfarin or similar agents requiring therapeutic monitoring. Note: Treatment with low molecular weight heparin is allowed. c) Treatment with anti therapy (aspirin at dose ≥ 300 mg/day, clopidogrel at dose ≥75 mg/day).
  25. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or IMP administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
  26. Anaphylaxis to ipilimumab, nivolumab, or any other monoclonal antibody, or any component of the IMPs prior to screening.
  27. History of psychotropic substance abuse or illicit drug use as judged by the investigator prior to screening.
  28. Pregnant and lactating women, and those intending to become pregnant during the study or within 5 months after the last study treatment.
  29. Currently participating in another clinical study prior to screening, or less than 4 weeks or 5 half-lives of the IMPs in the previous study, whichever is longer, between the screening of the study and the end of treatment in the previous study.
  30. Patients who have other conditions not suitable for inclusion per investigator's judgments.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
246 participants (estimated)

Study arms

  • Experimental
    HLX13 Group

    Drug: HLX13 · Drug: OPDIVO

  • Active comparator
    US-sourced YERVOY® Group

    Drug: Yervoy · Drug: OPDIVO

Interventions

  • DrugHLX13

    Patients will receive HLX13 (3 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.

  • DrugYervoy

    Patients will receive US-sourced YERVOY® (3 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.

  • DrugOPDIVO

    Patients will receive EU-sourced OPDIVO® (EU-sourced nivolumab) (1 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles. Subjects who may continue to benefit from OPDIVO® treatment as assessed by investigators will be subsequently treated with local-sourced OPDIVO® monotherapy every 4 weeks, up to 2 year after randomization.

06

What researchers measure

Primary outcomes

  1. Area under the serum concentration-time curve from time 0 to 21 days (AUC0-21d) after the 1st dose

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: from time 0 to 21 days after the 1st dose (3 weeks)

  2. Area under the serum concentration-time curve within a dosing interval at steady-state (AUCss) after the 4th dose

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: from time 0 to 78 days after the 4th dose (20 weeks)

Secondary outcomes

  1. Maximum serum drug concentration (Cmax)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: from time 0 to 78 days after the 4th dose (20 weeks)

  2. Maximum serum drug concentration at steady-state (Cmax,ss)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: from time 0 to 78 days after the 4th dose (20 weeks)

  3. Trough serum drug concentration (Ctrough)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: from time 0 to 78 days after the 4th dose (20 weeks)

  4. Trough serum drug concentration at steady-state (Ctrough,ss)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: from time 0 to 78 days after the 4th dose (20 weeks)

  5. Time to reach maximum serum drug concentration (Tmax)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: from time 0 to 78 days after the 4th dose (20 weeks)

  6. Time to reach maximum serum drug concentration at steady-state (Tmax,ss)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: from time 0 to 78 days after the 4th dose (20 weeks)

  7. Adverse events (AEs)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: From enrollment to the end of 90-day safety follow-up (21 weeks)

  8. Serious adverse events (SAEs)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: From enrollment to the end of 90-day safety follow-up (21 weeks)

  9. Adverse events of special interest (AESIs)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: From enrollment to the end of 90-day safety follow-up (21 weeks)

  10. Number of participants with abnormal vital signs

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: From enrollment to the end of 30-day safety follow-up (13 weeks)

  11. Number of participants with abnormal physical examination findings

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: From enrollment to the end of 30-day safety follow-up (13 weeks)

  12. Number of participants with abnormal Laboratory tests results (hematology, serum chemistry, endocrine function, coagulation function, and myocardial enzymes)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: From enrollment to the end of 30-day safety follow-up (13 weeks)

  13. Number of participants with abnormal 12-lead ECG readings

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: From enrollment to the end of 30-day safety follow-up (13 weeks)

  14. Objective response rate (ORR)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: From enrollment to the end of treatment (12 weeks)

  15. Time to response (TTR)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: From enrollment to the end of treatment (12 weeks)

  16. Incidence of anti-drug antibody (ADA)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: from time 0 to 78 days after the 4th dose (20 weeks)

  17. Incidence of neutralizing antibody (NAb)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: from time 0 to 78 days after the 4th dose (20 weeks)

07

Study locations

46 of 51 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 13 months is below that.

Counting every sponsor, half of 249 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2025
First posted
Sep 16, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07176650
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Nov 25, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 16, 2026

Study contacts

Henlius
Contact
Xuhui_Hu@henlius.com
+86-021-33395800

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HLX13

Start the discussion